Endogenic PharmacologyThe Canonical Reference
Delivery Platforms · Parenteral, Surgical, and Implantable Delivery

Parenteral and Surgical Delivery

Sterile aqueous saline with peptide-Opti-Salt for intravenous, intramuscular, subcutaneous, intra-articular, intrathecal, intraocular, surgical irrigation, joint lavage, and cardioplegia adjuvant use.

The Atumnus Bioregenic Saline™ Platform

Definition

Sterile aqueous saline with peptide-Opti-Salt for intravenous, intramuscular, subcutaneous, intra-articular, intrathecal, intraocular, surgical irrigation, joint lavage, and cardioplegia adjuvant use.

Full mechanistic definition forthcoming.


Pharmaceutical History

A documented format in pharmaceutical practice.

Historical timeline of the delivery format in the pharmaceutical literature — first characterization, commercial precedents, decades of regulatory-approved use — forthcoming.


Mechanism and Pharmacokinetics

How the format delivers.

Absorption pathway, bioavailability characteristics, first-pass metabolism considerations, onset and duration profiles — forthcoming.


Applicable Compounds

Bioregulators formulated for this platform.

Bioregulator-loaded sterile saline preparations for clinical, surgical, and IV-administered use.

See the full bioregulator class and the per-compound published literature for compound-specific research references.


Regulatory Pathway

Classification and oversight.

503A compounding, NDA pathways, and hospital-administered formulations.

Detailed regulatory analysis — agency-specific requirements, classification thresholds, and pathway-specific labeling considerations — forthcoming.


Peer-Reviewed Foundation

The format in the scientific literature.

PubMed-indexed peer-reviewed references establishing the format as legitimate pharmaceutical science — forthcoming.


The Atumnus Implementation

The Atumnus Bioregenic Saline™ platform.

The Bioregenic Saline™ platform is the Atumnus patent-pending embodiment of Parenteral and Surgical Delivery. It is licensed to operating affiliates for commercial development across the Opticeutical and Endoceutical tiers, and is one of the branded delivery technologies that anchors the Atumnus intellectual-property estate.

The Bioregenic Saline™ trademark and associated patent-pending technology are held by Atumnus LLC, the founding entity of endogenic pharmacology. See affiliated entities for institutional structure.


Related Platforms

Adjacent delivery formats.

Within the same cluster (Parenteral, Surgical, and Implantable Delivery), see the full set of delivery platforms in this category.

← Back to all delivery platforms